Dan Shochat | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Dan Shochat is active.

Explore More

Publication

Featured researches published by Dan Shochat.

Cancer Research | 1991

Pharmacokinetics and Immune Response of 131I-Chimeric Mouse/Human B72.3 (Human γ4) Monoclonal Antibody in Humans

M. B. Khazaeli; Mansoor N. Saleh; Tiepu Liu; Ruby F. Meredith; Richard H. Wheeler; Terry S. Baker; David M. King; David Secher; Laquetta Allen; Kim Rogers; David Colcher; Jeffrey Schlom; Dan Shochat; Albert F. LoBuglio

The Journal of Nuclear Medicine | 1992

Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.

Ruby F. Meredith; M. B. Khazaeli; Tiepu Liu; Gene Plott; Richard H. Wheeler; Charles D. Russell; David Colcher; Jeffrey Schlom; Dan Shochat; Albert F. LoBuglio

The Journal of Nuclear Medicine | 1992

Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.

Ruby F. Meredith; M. B. Khazaeli; Walter E. Plott; Mansoor N. Saleh; Tiepu Liu; Laquetta Allen; Charles D. Russell; Roger A. Orr; David Colcher; Jeffrey Schlom; Dan Shochat; Richard H. Wheeler; Albert F. LoBuglio

Cancer Research | 2001

Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.

André Trouet; Alexandre Passioukov; Kim Van derpoorten; Anne-Marie Fernandez; Jorge Abarca-Quinones; Roger Baurain; Thomas J. Lobl; Cecilia Oliyai; Dan Shochat; Vincent Dubois

Journal of Medicinal Chemistry | 2001

N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.

Anne-Marie Fernandez; K Van Derpoorten; Luc Dasnois; Karim Lebtahi; Vincent Dubois; Thomas J. Lobl; Sanjeev Gangwar; Cecilia Oliyai; Evan Lewis; Dan Shochat; André Trouet

Cancer biotherapy | 1993

A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1

Timothy M. Kuzel; Steven T. Rosen; A. Michael Zimmer; Edward A. Silverstein; Stewart Spies; Stephen L. Saletan; Mary E. Norvitch; Martin Birkhofer; Dan Shochat; Albert F. LoBuglio; Ruby F. Meredith; M. B. Khazaeli; Amy Polansky; Eddie Hu; David C. P. Chen; Kai Lee; Kristy Watkins

Archive | 1998

Radioprotectant for peptides labeled with radioisotope

Dan Shochat; Albert S. K. Chan; Michael J. Buckley; David Colcher

Cancer Research | 2002

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Vincent Dubois; Luc Dasnois; Karim Lebtahi; Françoise Collot; Nathalie Heylen; Nathalie Havaux; Anne-Marie Fernandez; Thomas J. Lobl; Cecilia Oliyai; Matthew H. Nieder; Dan Shochat; Geoffrey T. Yarranton; André Trouet

Blood | 2011

A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results

Anne E. Hagey; Jeffrey E. Lancet; Varghese Palath; Andrew Wei; Martin Lackmann; Jorge Cortes; Andrew W. Boyd; Dan Shochat; Geoffrey T. Yarranton; Christopher Bebbington; Jonathan A. Leff

Archive | 1998